DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Indirect Comparison Between Eltrombopag & Romiplostim

Information source: GlaxoSmithKline
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Thrombocytopaenia

Intervention: Eltrombopag (Drug); Romiplostim (Drug); Placebo (Drug)

Phase: N/A

Status: Completed

Sponsored by: GlaxoSmithKline

Official(s) and/or principal investigator(s):
GSK Clinical Trials, Study Director, Affiliation: GlaxoSmithKline

Summary

An indirect comparison to compare the efficacy of eltrombopag versus romiplostim

Clinical Details

Official title: Indirect Comparison of Efficacy of Treatments for Idiopathic Immune Thrombocytopenic Purpura - Review of Platelet Responses and Bleeding Events

Study design: Time Perspective: Retrospective

Primary outcome:

Durable response: platelet count of >=50 and <400 Gi/L

Overall response: either a durable response or a transient platelet response

Detailed description: An indirect analysis was conducted to evaluate the relative efficacy of eltrombopag and romiplostim using placebo as a common comparator

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Adults with ITP

- Pre-specified treatment

- Prospective clinical studies with at least 10 patients

Exclusion Criteria:

- Adults with ITP for other reasons

Locations and Contacts

Additional Information

Starting date: August 2009
Last updated: November 3, 2011

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017